Skip Navigation LinksHome > November 2011 - Volume 19 - Issue 6 > Retrospective Study of Prolonged Versus Intermittent Infusio...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0b013e31822e9bf5
Original Articles

Retrospective Study of Prolonged Versus Intermittent Infusion Piperacillin-Tazobactam and Meropenem in Intensive Care Unit Patients at an Academic Medical Center

Dow, Rebekka J. PharmD*; Rose, Warren E. PharmD†; Fox, Barry C. MD‡; Thorpe, Joshua M. PhD, MPH§; Fish, Jeffrey T. PharmD∥

Collapse Box

Abstract

Background: Prolonged infusions of β-lactams are increasingly being utilized because of increased antimicrobial resistance and a lack of new antibiotics in the pipeline.

Methods: A retrospective, observational study evaluated adult patients who received at least 72 hours of piperacillin-tazobactam or meropenem in a medical and surgical intensive care unit (ICU) at an academic medical center. In the first 6 months of the study, all patients received conventional intermittent dosing; in the second 6 months, all patients received these antibiotics by prolonged infusions. The main outcome comparisons between groups were duration of ventilator support, duration of ICU and hospital length of stay, and in-hospital mortality.

Results: A total of 121 patients were included: 54 patients in the intermittent (67% piperacillin-tazobactam, 33% meropenem) and 67 patients in the prolonged group (81% piperacillin-tazobactam, 19% meropenem). The prolonged group demonstrated a significant decrease in ventilator days (−7.2 days; 95% confidence interval [CI], −12.4 to −2.4), ICU length of stay (−4.5 days; 95% CI, −8.3 to −1.4), and hospital length of stay (−8.5 days; 95% CI, −18.7 to −1.2) compared with the intermittent group. The risk of in-hospital mortality was 12.4% in the prolonged infusion group and 20.7% in the intermittent infusion group corresponding to an odds ratio of 0.54 (0.18-1.66).

Conclusions: The results of this study show that the use of prolonged infusions of piperacillin-tazobactam and meropenem could potentially improve clinical outcomes in critically ill populations. As antibiotic resistance continues to increase in gram-negative pathogens, these β-lactam dosing strategies will be important for appropriate treatment.

© 2011 Lippincott Williams & Wilkins, Inc.

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.